Lebrikizumab Treatment Improves Quality of Life in Patients with Moderate-to-Severe Atopic Dermatitis: Results from Two Phase 3, Randomized, Double-Blinded, Placebo-Controlled Trials (ADvocate1 and ADvocate2)